Aker BioMarine ASA (the "Company") has renewed its offer of new shares to
employees in the Company and its Norwegian subsidiaries on similar terms as for
the last 3 previous years (the "Employee Share Purchase Program"). The deadline
for acceptance of the offer in the Employee Share Purchase Program expired on 21
Feb 2025, at 16:30 CET.

The offer price for the shares in the Employee Share Purchase Program has been
set to approximately NOK 54,56 (the "Offer Price"). The Offer Price is based on
the volume-weighted average share price for the Company's shares on the Oslo
Stock Exchange during the last five trading days prior to, and including, the
last day of the application period, with a discount of 20%. Any shares acquired
in the Employee Share Purchase Program will be subject to a lock-up period of
two years, and the reduced offer price shall reflect the value-reducing effect
of the lock-up period.

Based on the applications received in the Employee Share Purchase Program, the
board of directors of the Company has allocated a total of 18,385 new shares to
the participants in the Employee Share Purchase Program (the "Program Shares").

Furthermore, the board of directors has, on the basis of the authorisation
granted to it by the annual general meeting held on 16 April 2024, resolved to
increase the share capital of the Company with NOK 110 310, by issuance of
18,385 new shares, each with a nominal value of NOK 6.00, at a subscription
price equal to the Offer Price. The Program Shares comprise approximately 0.01%
of the existing and outstanding shares in the Company prior to their issuance.

Following the registration of the share capital increase with the Norwegian
Register of Business Enterprises (Nw.: Foretaksregisteret), the new share
capital of the Company will be NOK 526 220 394, divided into 87 703 399 shares,
each with a nominal value of NOK 6.00.

For further information, please contact 
Christopher Robin Vinter, VP Strategic Finance & IR 
Mobile: +47 911 60 820 
Email: Christopher.vinter@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine:
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and
PL+, as well as the consumer brand, Kori Krill. The innovative approach also
extends into the spin-offs AION (reduce and recycle plastic waste across
industries) and Understory (a protein brand). Aker BioMarine is listed on the
Oslo Stock Exchange (AKBM). More information is available at
www.akerbiomarine.com.